A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma

References

• Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492.
   PubMed Web of Science ®Google Scholar
• Spatz A, Cook MG, Elder DE, et al. Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer. 2003;39(13):1861–1865.
   PubMed Web of Science ®Google Scholar
• Warycha MA, Christos PJ, Mazumdar M, et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer. 2008;113(12):3341–3348.
   PubMed Web of Science ®Google Scholar
• Jewell R, Elliott F, Laye J, et al. The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell Melanoma Res. 2015;28(1):94–104.
   PubMed Web of Science ®Google Scholar
• Rakosy Z, Ecsedi S, Toth R, et al. Integrative genomics identifies gene signature associated with melanoma ulceration. PLoS One. 2013;8(1):e54958.
   PubMed Web of Science ®Google Scholar
• Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res. 2000;6(5):1845–1853.
   PubMed Web of Science ®Google Scholar
• Ladstein RG, Bachmann IM, Straume O, et al. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 2010;10:140.
   PubMed Web of Science ®Google Scholar
• Jonsson G, Busch C, Knappskog S, et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res. 2010;16(13):3356–3367.
   PubMed Web of Science ®Google Scholar
• Bogunovic D, O’Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106(48):20429–20434.
   PubMed Web of Science ®Google Scholar
• Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98(7):472–482.
   PubMedGoogle Scholar
• Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27(12):1571–1576.
   PubMed Web of Science ®Google Scholar
• Bonnelykke-Behrndtz LM, Schmidt H, Damsgaard TE, et al. Consumption of the epidermis: a suggested precursor of ulceration associated with increased proliferation of melanoma cells. Am J Dermatopathol. 2015;37(11):841–845.
   PubMed Web of Science ®Google Scholar
• Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77(7):1303–1310.
   PubMed Web of Science ®Google Scholar
• Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31(33):4252–4259.
   PubMed Web of Science ®Google Scholar
• de Moll EH, Fu Y, Qian Y, et al. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunol Immunother. 2015;64(9):1193–1203.
   PubMed Web of Science ®Google Scholar
• Mar VJ, Liu W, Devitt B, et al. The role of BRAF mutations in primary melanoma growth rate and survival. Br J Dermatol. 2015;173(1):76–82.
   PubMed Web of Science ®Google Scholar
• Thomas NE, Edmiston SN, Alexander A, et al. Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma. JAMA Oncol. 2015;1(3):359–368.
   PubMed Web of Science ®Google Scholar
• Nagore E, Requena C, Traves V, et al. Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol. 2014;70(5):858–862.e1–2.
   PubMed Web of Science ®Google Scholar
• Heppt MV, Siepmann T, Engel J, et al. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer. 2017;17(1):536.
   PubMedGoogle Scholar
• Ellerhorst JA, Greene VR, Ekmekcioglu S, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011;17(2):229–235.
   PubMed Web of Science ®Google Scholar
• Akslen LA, Angelini S, Straume O, et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol. 2005;125(2):312–317.
   PubMed Web of Science ®Google Scholar
• Ny L, Hernberg M, Nyakas M, et al. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. Acta Oncol. 2020;59(7):833–844.
   PubMed Web of Science ®Google Scholar
• Bombonato C, Ribero S, Pozzobon FC, et al. Association between dermoscopic and reflectance confocal microscopy features of cutaneous melanoma with BRAF mutational status. J Eur Acad Dermatol Venereol. 2017;31(4):643–649.
   PubMed Web of Science ®Google Scholar
• Jovanovic B, Krockel D, Linden D, et al. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol. 2008;128(11):2696–2704.
   PubMed Web of Science ®Google Scholar
• Harbst K, Staaf J, Masback A, et al. Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Res. 2010;20(5):381–391.
   PubMed Web of Science ®Google Scholar
• Yancovitz M, Litterman A, Yoon J, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One. 2012;7(1):e29336.
   PubMed Web of Science ®Google Scholar
• Helias-Rodzewicz Z, Funck-Brentano E, Baudoux L, et al. Variations of BRAF mutant allele percentage in melanomas. BMC Cancer. 2015;15(1):497.
   PubMedGoogle Scholar
• Falkenius J, Lundeberg J, Johansson H, et al. High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma. Melanoma Res. 2013;23(6):452–460.
   PubMed Web of Science ®Google Scholar
• Falkenius J, Johansson H, Tuominen R, et al. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. BMC Cancer. 2017;17(1):584.
   PubMedGoogle Scholar
• Satzger I, Marks L, Kerick M, et al. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Oncotarget. 2015;6(35):37895–37905.
   PubMedGoogle Scholar
• Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014;20(7):1965–1977.
   PubMed Web of Science ®Google Scholar
• Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30(20):2522–2529.
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Baiter M, Kuhnapfel S, et al. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer. 2013;109(11):2833–2841.
   PubMed Web of Science ®Google Scholar
• Nielsen LB, Dabrosin N, Sloth K, et al. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases. Histopathology. 2018;72(5):814–825.
   PubMed Web of Science ®Google Scholar
• Omholt K, Platz A, Kanter L, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9(17):6483–6488.
   PubMed Web of Science ®Google Scholar
• Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: a meta-analysis. Eur J Cancer. 2017;81:106–115.
   PubMed Web of Science ®Google Scholar
• Edlundh-Rose E, Egyhazi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006;16(6):471–478.
   PubMed Web of Science ®Google Scholar
• Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239–1246.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Gos A, Jurkowska M, et al. Molecular alterations in clinical stage III cutaneous melanoma: correlation with clinicopathological features and patient outcome. Oncol Lett. 2014;8(1):47–54.
   PubMed Web of Science ®Google Scholar
• Hugdahl E, Kalvenes MB, Puntervoll HE, et al. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer. 2016;114(7):801–808.
   PubMed Web of Science ®Google Scholar
• Pearlstein MV, Zedek DC, Ollila DW, et al. Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. J Cutan Pathol. 2014;41(9):724–732.
   PubMed Web of Science ®Google Scholar
• Stagni C, Zamuner C, Elefanti L, et al. BRAF gene copy number and mutant allele frequency correlate with time to progression in metastatic melanoma patients treated with MAPK inhibitors. Mol Cancer Ther. 2018;17(6):1332–1340.
   PubMed Web of Science ®Google Scholar
• Macerola E, Loggini B, Giannini R, et al. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch. 2015;467(2):177–184.
   PubMed Web of Science ®Google Scholar
• Klein O, Clements A, Menzies AM, et al. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer. 2013;49(5):1073–1079.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–332.
   PubMed Web of Science ®Google Scholar
• Busser B, Leccia MT, Gras-Combe G, et al. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma. JAMA Dermatol. 2013;149(12):1403–1406.
   PubMed Web of Science ®Google Scholar
• Trudel S, Odolczyk N, Dremaux J, et al. The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma. BMC Cancer. 2014;14:727.
   PubMed Web of Science ®Google Scholar
• Colomba E, Helias-Rodzewicz Z, Von Deimling A, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15(1):94–100.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012;48(2):218–225.
   PubMed Web of Science ®Google Scholar
• Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23(31):8048–8056.
   PubMed Web of Science ®Google Scholar